Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Iovance Biotherapeutics (IOVA) Shares Outstanding (Diluted Average): 2023-2025

Historic Shares Outstanding (Diluted Average) for Iovance Biotherapeutics (IOVA) over the last 2 years, with Jun 2025 value amounting to $334,511.

  • Iovance Biotherapeutics' Shares Outstanding (Diluted Average) rose 17.45% to $334,511 in Q2 2025 from the same period last year, while for Jun 2025 it was $334,511, marking a year-over-year increase of 17.45%. This contributed to the annual value of $289,877 for FY2024, which is 23.28% up from last year.
  • According to the latest figures from Q2 2025, Iovance Biotherapeutics' Shares Outstanding (Diluted Average) is $334,511, which was up 3.61% from $322,868 recorded in Q1 2025.
  • Iovance Biotherapeutics' 5-year Shares Outstanding (Diluted Average) high stood at $213.7 million for Q1 2023, and its period low was $224,481 during Q2 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $21.6 million, with a median of $287,347 in 2024.
  • The largest annual percentage gain for Iovance Biotherapeutics' Shares Outstanding (Diluted Average) in the last 5 years was 26.88% (2024), contrasted with its biggest fall of 99.88% (2024).
  • Iovance Biotherapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $235,131 in 2023, then increased by 23.28% to $289,877 in 2024, then grew by 17.45% to $334,511 in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $334,511 for Q2 2025, versus $322,868 for Q1 2025 and $289,877 for Q4 2024.